This portion of the prospectus appears to imply that the intention is for CHM to essentially be commercial arm for CTLX CAR T cell therapies, whether in its current form or following any and all modifications made to this technology. It's fascinating stuff to see how City of Hope (Beckman Institute) are looking to apply this technology, with CHM looking to sublease should clinical trials be successful.
(a) defining the scope of tumours potentially amenable to CLTX-CAR T cell therapy; This covers the current use of the technology
(b) investigating the pairing of CLTX-CAR T cell therapy with other Glioblastoma therapeutic strategies;Exploring effectiveness of the current technology as a combination therapy.
(c) exploring the enhancement of the activity of the present CLTX-CAR construct;For example, to either modify the current CLTX construct to enhance specificity to other types of cancers or to optimise through modifying non-targeting domains as mentioned here:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7500824/(d) developing dual-targeting CARs incorporating CLTX; To make a significant modification to the current construct to make it into hybrid construct of sorts.
(e) investigating other potential broadly-acting CAR targeting strategies for solid tumours; andTo incorporate a new construct?
(f) exploring other research areas, such as generating different immune cell products or assessing the ability to generate allogeneic CLTX-CAR T productsAs described.
And to achieve these developments, CHM have to: 
All of this makes a 90 mill market cap look cheap.
(20min delay)